Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that CD33 + status confers therapeutic sensitivity to Cytarabine, Daunorubicin, Gemtuzumab ozogamicin in patients with Acute Lymphoid Leukemia.
The Republic of Ireland's Health Service Executive (HSE) has approved gemtuzumab ozogamicin in combination with daunorubicin and cytarabine for reimbursement as a treatment option for the treatment of patients aged 15 years and above with previously untreated, de novo CD33 positive Acute Myeloid Leukemia (AML), except acute promyelocytic leukemia.
This statement is based on a regulatory approval from the Health Service Executive:
Gemtuzumab ozogamicin is indicated for combination therapy with DAUNOrubicin and cytarabine for the treatment of patients age 15 years and above with previously untreated, de novo CD33 positive Acute Myeloid Leukemia (AML), except acute promyelocytic leukaemia